Link to this page
Melanoma Ontology
| Preferred Name | Nivolumab | |
| Synonyms |
BMS-936558 MDX-1106 NIVO NIVOLUMAB Nivolumab ONO-4538 Opdivo |
|
| Definitions |
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C68814 |
|
| Accepted_Therapeutic_Use_For |
locally advanced or metastatic urothelial carcinoma; recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN); renal cell carcinoma (RCC) ; metastatic melanoma; non-small cell lung cancer (NSCLC); classical Hodgkin lymphoma (cHL); BRAF V600 wild-type, unresectable or metastatic melanoma; metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.
|
|
| CAS_Registry |
946414-94-4
|
|
| code |
C68814
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
|
|
| Display_Name |
Nivolumab
|
|
| FDA_UNII_Code |
31YO63LBSN
|
|
| has exact synonym |
BMS-936558 MDX-1106 NIVO NIVOLUMAB Nivolumab ONO-4538 Opdivo
|
|
| Has_Target | ||
| imported from | ||
| in_subset |
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116978 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C63923 http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C157711 |
|
| label |
Nivolumab
|
|
| Legacy_Concept_Name |
Anti-PD-1_Human_Monoclonal_Antibody_MDX-1106
|
|
| PDQ_Closed_Trial_Search_ID |
539733
|
|
| PDQ_Open_Trial_Search_ID |
539733
|
|
| Preferred_Name |
Nivolumab
|
|
| prefixIRI |
NCIT:C68814
|
|
| prefLabel |
Nivolumab
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor
|
|
| UMLS_CUI |
C3657270
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |